<DOC>
	<DOCNO>NCT02605083</DOCNO>
	<brief_summary>This clinical trial Phase 1-2 , open-label , sequential-group , dose-escalation cohort-expansion study evaluate safety , pharmacokinetics , pharmacodynamics , antitumor activity daily oral administration eFT508 .</brief_summary>
	<brief_title>A Dose Escalation Cohort-Expansion Study Oral eFT508 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>eFT508 oral , potent highly selective inhibitor mitogen-activated protein kinase interact kinase ( MNK ) 1 2 . Dysregulated translation messenger RNA ( mRNA ) play role pathogenesis multiple solid tumor hematological malignancy . MNK1 MNK2 integrate signal several oncogenic immune signal pathway ( include RAS , p38 Toll-like receptor ) phosphorylating eukaryotic initiation factor 4E ( eIF4E ) key effector protein . Phosphorylation regulatory protein MNK1 MNK2 selectively regulate stability translation subset cellular mRNA control tumor growth , tumor microenvironment immune signal . Nonclinical study indicate eFT508 show activity various type solid tumor . These nonclinical study support initiation clinical development eFT508 patient cancer .</detailed_description>
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 2 . Pathologically documented diagnosis advance solid tumor malignancy progress appropriate prior therapy potential cure currently available treatment . 3 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) outside prior radiation field . 4 . At least 3 week post treatments/therapies time first dose . 5 . Adequate bone marrow function . 6 . Adequate hepatic function . 7 . Adequate renal function . 8 . Normal coagulation panel . 9 . Negative antiviral serology . 10 . Willingness use effective contraception . 1 . Known central nervous system malignancy . 2 . Gastrointestinal disease may interfere drug absorption . 3 . Significant cardiovascular disease . 4 . Significant ECG abnormality . 5 . Ongoing risk bleed due active peptic ulcer disease , bleed diathesis , requirement systemic anticoagulant . Use heparin thrombolytic agent local maintenance clearance central venous catheter permit . 6 . Ongoing systemic bacterial , fungal viral infection ( exception fungal infection skin nail ) . 7 . Pregnancy breastfeed . 8 . Major surgery within 4 week start study therapy . 9 . Prior solid organ bone marrow progenitor cell transplantation . 10 . Prior therapy know inhibitor MNK1 MNK2 . 11 . Ongoing immunosuppressive therapy , include systemic enteric corticosteroid ( use topical inhaled corticosteroid ) . 12 . Use drug could prolong QT interval within 7 day start study therapy . 13 . Use drug might pose risk drugdrug interaction within 47 day start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Breast</keyword>
	<keyword>Head Neck</keyword>
	<keyword>Lung</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Colon</keyword>
	<keyword>Renal</keyword>
	<keyword>Thyroid</keyword>
	<keyword>Prostate</keyword>
	<keyword>Ovarian</keyword>
	<keyword>MNK1</keyword>
	<keyword>MNK2</keyword>
	<keyword>eIF4E</keyword>
</DOC>